Whalesbook
Dr Reddy's Laboratories launched an over-the-counter (OTC) generic ophthalmic solution on Wednesday in the US after securing approval from the U.S. Food and Drug Administration (FDA). The product, Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7 per cent, is an antihistamine eye drop formulated for the temporary relief of itchy eyes caused by common allergens.
Strategic Market Entry
This launch strengthens Dr Reddy's existing offerings in the OTC eye-care segment, which already includes 0.2 per cent and 0.1 per cent strengths of the same active ingredient. Milan Kalawadia, CEO of North America Generics at Dr Reddy's, highlighted this addition as a move that bolsters their portfolio. The company views this as its first-to-market launch for this specific strength, underscoring its robust capabilities in developing and bringing store-brand equivalents of established over-the-counter brands to the U.S. market. This strategic approach targets a lucrative segment of the consumer health industry.
Market Potential
The market opportunity is substantial, as indicated by data from NIQ. The Pataday brand, a comparable product, recorded sales of approximately $69.9 million in the U.S. during the 52-week period concluding on December 27, 2025. This figure provides a benchmark for the potential revenue generation from this product category. Dr Reddy's shares closed down 0.33% at ₹1,186.45 on the BSE on Wednesday.